Picture of Fulgent Genetics logo

FLGT — Fulgent Genetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Fulgent Genetics Inc expected to post a loss of 43 cents a share - Earnings Preview

* Fulgent Genetics Inc  FLGT.OQ   FLGT.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 5. 
    * The El Monte California-based  company is expected to
report  a
81.2% decrease in revenue to $60.052 million from $320.27
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. The company's guidance on
February 28 2023, for the period ended March 31, was for revenue
of $56.000 million.
    * ​Refinitiv's mean analyst estimate for Fulgent Genetics
Inc is
for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $45​, above​ its last closing price of $29.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.56       -0.56      -0.48     Beat    14.3
 Sep. 30 2022  0.05        0.05       0.32      Beat    498.1
 Jun. 30 2022  0.73        0.73       0.78      Beat    6.8​
 Mar. 31 2022  3.84        3.86       5.08      Beat    31.6
 ​​Dec.        2.61        2.61       3.34      Beat    28.1
 31 2021                                                
 Sep. 30 2021  3.25        3.25       3.95      Beat    21.7​
 Jun. 30 2021  2.78        2.76       2.47      Missed  -10.4
 Mar. 31 2021  5.82        5.86       6.59      Beat    12.5
 This summary was machine generated May 3 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Fulgent Genetics

See all news